An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations

Trial Profile

An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2016

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Ketoconazole; Midazolam; Rifampicin
  • Indications Haematological malignancies
  • Focus Pharmacokinetics
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 26 Apr 2016 Results of patients with Haematological malignancies and hepatic or renal impairment (n=17) published in the British Journal of Clinical Pharmacology
    • 26 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 May 2013 Planned End Date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top